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Abstract
Pulmonary surfactant is a surface active material composed of both lipids and proteins that is produced
by alveolar type II pneumocytes. Abnormalities of surfactant in the immature lung or in the acutely
inflamed mature lung are well described. However, in a variety of subacute diseases of the mature lung,
abnormalities of lung surfactant may also be of importance. These diseases include chronic obstructive
pulmonary disease, asthma, cystic fibrosis, interstitial lung disease, pneumonia, and alveolar
proteinosis. Understanding of the mechanisms that disturb the lung surfactant system may lead to novel
rational therapies for these diseases.
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Introduction
Lung surfactant is a highly surface active substance that is
synthesized by alveolar epithelial type II cells and com-
posed of approximately 80% phospholipids, 10% proteins,
and 10% neutral lipids. The predominate phospholipids are
phosphatidylcholine (PC) and phosphatidylglycerol; phos-
phatidylinositol and sphingomyelin contribute to the total
concentration. Two of the surfactant-associated proteins,
SP-A and SP-D, have important host defense properties
[1], while the remaining two, SP-B and SP-C, are intensely
hydrophobic and interact with surfactant phospholipids to
optimize surface tension lowering function. After synthesis,
surfactant is stored in lamellar bodies and subsequently se-
creted in an organized tubular myelin form, which exists in
the alveolar lining fluid subphase. It is from tubular myelin
that the surfactant film is formed.
Surfactant recovered by alveolar lavage may be separated
by centrifugation into two fractions: a highly surface active
sedimenting fraction termed 'large aggregates', composed
of lamellar myelin, tubular myelin and lipid arrays; and a
poorly surface active, nonsedimenting 'small aggregate'
fraction. Surfactant not only maintains alveolar stability, but
it is also is present in small airways and promotes their pa-
tency [2]. Alveolar surfactant is the major source of sur-
factant found in both distal and proximal airways.
Mechanisms of surfactant dysfunction
A variety of pathologic processes may modify surfactant
abundance, structure, and/or function. Genetic alterations
of coding or noncoding regions of SP-B or SP-C may be re-
lated to the development of pulmonary disease in the adult
[3,4]. Surfactant inactivation can be the result of functional
inhibition in the presence of such substances as albumin,
hemoglobin, fatty acids, or arachidonic acid. Such inactiva-
tion can be overcome by addition of excess surfactant [5].
In addition, proteolytic enzymes or phospholipases can
cleave surfactant components with consequent loss of
function. Other processes that can cause surfactant inacti-
vation include nitration and oxidation, with consequences
that include inactivation of SP-A [6]. Accelerated conver-
sion of surfactant from the highly functional large aggregate
form to the poorly functioning small aggregate form is an-
other mechanism of surfactant inactivation.
Received: 1 November 2001
Revisions requested: 9 January 2002
Revisions received: 18 February 2002
Accepted: 20 February 2002
Published: 4 April 2002
Respir Res 2002, 3:19
© 2002 BioMed Central Ltd
(Print ISSN 1465-9921; Online ISSN 1465-993X) Respiratory Research   Vol 3 No 1   Devendra and Spragg
Page 2 of 4
(page number not for citation purposes)
Obstructive lung disease
Asthma
Models of airway closure suggest a theoretical use of sur-
factant in asthma, and clinical studies have suggested that
surfactant from asthmatics is functionally impaired [7,8].
The main mechanism of this impairment is thought to be the
influx of inhibitory proteins into the airways, although chang-
es in surfactant composition may occur [9]. Data from ani-
mal experiments also suggest a role for surfactant in the
pathogenesis of asthma. Becher found that sensitized guin-
ea pigs that have had surfactant prophylactically adminis-
tered show attenuated bronchiolar constriction in response
to ovalbumin challenge [10]. Other investigators have
shown in animal models of asthma that even though there
is little change in the amount of surfactant, it may be in a
less functional form. Cheng and colleagues demonstrated
that, in a guinea-pig model of chronic asthma, the content
of large surfactant aggregates was decreased [11]. The
surfactant pool size was also decreased. Thus, these find-
ings suggest enhanced conversion to small aggregate
forms and either that the amount of surfactant secreted
may be decreased or that there is increased uptake of the
extracellular surfactant.
In the setting of either chronic or acute asthma, products of
inflammatory cells (including proteases and reactive oxy-
gen and nitrogen species) and airway edema may contrib-
ute to surfactant dysfunction. At present, the contribution of
surfactant in the asthmatic process is unclear.
Clinical use of surfactant in asthma is currently under inves-
tigation. A study in which 12 asthmatic children received
aerosolized bovine surfactant indicated that the there was
no change in forced vital capacity, forced expiratory volume
in 1 s, peak expiratory flow, and mean forced expiratory flow
during the middle half of the forced vital capacity [12]. In
another clinical trial, 11 adult asthmatic patients with stable
airway obstruction six hours after an asthma attack were
given aerosolized surfactant [13]. All patients showed an
improvement in pulmonary function. Larger trials are indi-
cated to evaluate these observations.
Smoking and chronic obstructive pulmonary disease
Smoking plays a role not only in the pathogenesis of the al-
veolar destruction and airway inflammation found in chronic
obstructive pulmonary disease (COPD) patients, but also
in altering surfactant composition and function. As re-
viewed by Hohlfeld et al., smokers are likely to have a de-
crease in the phospholipid content of bronchoalveolar
lavage (BAL) fluid and impaired surface activity of sur-
factant recovered from BAL fluid [7]. Smoking might affect
surfactant homeostasis and function through both direct
and indirect mechanisms. The particulate phase of ciga-
rette smoke has been demonstrated to impair surfactant
function directly. Also, type II pneumocytes exposed direct-
ly to cigarette smoke in culture have decreased secretion
of PC [14].
Indirectly, cigarette smoking causes airway inflammation
with subsequent effects on surfactant function due, in part,
to products of activated neutrophils. The activity of neu-
trophil elastase is particularly augmented, as constituents
of cigarette smoke (nitrites and oxidants) can inactivate α 1-
proteinase inhibitor, a critical inhibitor of elastase activity. In
addition, cigarette smoke can activate macrophages, re-
sulting in increased oxygen radical production [15].
The aggregate effects of cigarette smoke on lung sur-
factant are likely to result in a significant loss of surface ten-
sion lowering function and increase in pressure gradient
across the alveolar wall. As extracellular matrix components
of the alveolar wall may be partially disrupted in the chronic
smoker, this increased pressure gradient may contribute to
alveolar wall rupture and the development of emphysema.
Host defense functions of surfactant may also be impaired
in the chronic smoker. Levels of both SP-A and SP-D are
decreased in BAL fluid recovered from chronic smokers
and, given the importance of these two surfactant proteins
in host defense, these changes may contribute to the in-
creased incidence of respiratory infections [16].
There is limited information on the value of surfactant treat-
ment of patients with COPD. In a single study of the effect
of surfactant phospholipid in COPD, patients with chronic
bronchitis who received aerosolized phospholipid three
times daily for two weeks had a modest improvement in air-
flow compared to that in patients who received saline [17].
Cystic fibrosis
Analysis of BAL fluid from adults with cystic fibrosis (CF)
discloses a decrease in the content of intact SP-A and ev-
idence of proteolytic cleavage of SP-A [18,19]. As SP-A
may be of critical importance in host bacterial defense [1],
its loss may predispose to lung infection in CF patients.
Surface tension lowering function of surfactant from CF pa-
tients is also impaired, and alterations in surfactant lipid
composition may contribute to this impairment. A pilot
study investigating the consequences of administering a
natural surfactant aerosol to CF patients daily for five days
showed no evidence of acute or short-term benefit [20].
Pneumonia
Surfactant recovered in BAL fluid from patients with pneu-
monia has reduced PC and phosphatidylglycerol content,
and alterations in fatty acid composition. These changes
are qualitatively similar to those observed in patients with
acute respiratory distress syndrome. In addition, the
amount of SP-A is also decreased and surfactant surface
tension lowering function is impaired, due, in part, to the al-Available online http://respiratory-research.com/content/3/1/19
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terations in lipid components [21]. As found in other condi-
tions where hydrophilic surfactant protein content is
diminished, host defense functions may be impaired. Limit-
ed experience with selective bronchial instillation of sur-
factant in a patient with pneumonia has suggested the
possibility of benefit [22].
Interstitial lung disease
Idiopathic pulmonary fibrosis
Recent changes in the definition of idiopathic pulmonary fi-
brosis (IPF) may confuse interpretation of prior clinical
studies. The pathological classification of usual interstitial
pneumonia is now commonly called IPF, whereas previous-
ly patients who had a more cellular IPF were classified as
having nonspecific interstitial pneumonia. Given that the
nomenclature is confusing, existing data may be from a mix-
ture of patients with usual interstitial pneumonia and non-
specific interstitial pneumonia. Nevertheless, IPF studies
suggest that the total amount of surfactant phospholipid is
decreased and that the composition is altered, with a de-
crease in the fractional content of phosphatidylglycerol and
an increase in that of phosphatidylinositol and sphingomy-
elin. In addition, the concentration of large surfactant ag-
gregates is also decreased in patients with IPF, as is the
surface tension lowering ability of this surfactant [23].
Decreases in the SP-A content of BAL fluid from patients
with IPF have also been reported. Günther et al. found that
the concentration of SP-A in BAL fluid was 1121 ± 252 ng/
ml versus 1529 ± 136 ng/ml in BAL fluid from control pa-
tients [23]. When normalized to phospholipid, the values
also showed a modest but significant decrease. These
changes in surfactant apoprotein and phospholipid levels
may be due to underlying parenchymal destruction in pa-
tients with IPF.
Recent data suggest that serum SP-A levels may be of val-
ue in predicting the course of patients with IPF. Takahashi
et al. found that patients with normal serum SP-A levels had
a better prognosis than those with elevated serum levels
[24]. They also found that elevated serum SP-D levels cor-
related with the rate of decline of vital capacity and total
lung capacity. McCormack et al. also found that BAL fluid
levels of phospholipid and SP-A, and the SP-A/phospholi-
pid ratio (SP-A/PL) could be used to predict the outcome
[25]. Patients who had a SP-A/PL ratio of less than 29.6
µg/µmol had a five-year survival rate of 30% whereas those
who had a SP-A/PL ratio greater than 29.6 µg/µmol had a
five-year survival rate of 68%. The benefit of surfactant as a
therapy in IPF has not been investigated.
Sarcoidosis
Sarcoidosis is a multisystem, granulomatous disease with
a predilection for involvement of the lung. The concentra-
tion of SP-A in BAL fluid is either unchanged or increased,
but when normalized to phospholipid content, the SP-A/PL
value may be decreased relative to controls. The SP-B lev-
els in BAL fluid are increased, but when normalized to
phospholipid, values are unchanged relative to controls
[23,26]. According to most reports, the amount and frac-
tional content of surfactant phospholipid recovered in BAL
fluid from patients with sarcoidosis is unchanged from con-
trols. As with IPF the surface activity of surfactant in pa-
tients with sarcoidosis is impaired and there is a reduction
in the large aggregate pool size [23]. The responsible
mechanisms and pathophysiologic relevance of these ob-
servations are unclear.
Hypersensitivity pneumonitis
Hypersensitivity pneumonitis, also called allergic alveolitis,
may be due to a wide variety of antigenic stimuli. The frac-
tional content of large surfactant aggregates and the phos-
pholipid content of BAL fluid from these patients is not
significantly different from that of healthy patients, although
subtle differences in the fractional content of phosphati-
dylglycerol and sphingomyelin have been reported [23].
Changes in the level of SP-A are conflicting, with reports of
both significant decreases [23] and increases [26]. SP-B
levels are reported to be the same as those of controls [23].
Pulmonary alveolar proteinosis
The adult form of pulmonary alveolar proteinosis (PAP) is a
rare idiopathic disease characterized by massive accumu-
lation of surfactant in alveoli. The exact defect is unclear,
but it may be related to lack of granulocyte-macrophage
colony-stimulating factor (GM-CSF) or GM-CSF receptor
β c chain. These defects contribute to reduced clearance of
surfactant from the alveoli. Mice deficient in GM-CSF show
the same clinical disease as humans with PAP [27]. When
GM-CSF knockout mice were given exogenous GM-CSF
by inhalation for five weeks, the histopathology, PC pool
size, and SP-B concentrations returned to normal. With-
drawal of inhaled GM-CSF resulted in return to the alveolar
proteinosis phenotype. Mice lacking the GM-CSF receptor
β c chain also had the same histopathology as the GM-CSF
deficient mice, but the concentrations of PC and of the sur-
factant proteins were lower, indicating that the severity of
PAP symptoms may be regulated by different mutations.
Other clinical reports indicate that some cases of idiopathic
PAP may be due to an autoimmune disorder. Neutralizing
antibodies to GM-CSF have been described in certain pa-
tients with PAP [28]. Other investigators have shown that
there is marked heterogeneity of mass and charge in the
SP-A isoforms in patients with PAP, and elevation in the
content of SP-A, SP-B, and SP-C occurs [29,30]. It is un-
clear whether these lung surfactant modifications are sec-
ondary effects or have a pathogenic role.
The traditional method of treating patients with PAP is
whole lung lavage with saline. Recent trials, however, haveRespiratory Research   Vol 3 No 1   Devendra and Spragg
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examined the value of recombinant GM-CSF administra-
tion. In a preliminary study, Kavuru and colleagues showed
that the use of GM-CSF was beneficial in increasing the
partial pressure of oxygen in arterial blood and decreasing
the alveolar-arterial oxygen gradient in four patients with
PAP [31]. This is a promising area of clinical investigation
that will require additional clinical investigation.
Conclusion
In acute diseases, surfactant has been used in the treat-
ment of infant respiratory distress syndrome and meconium
aspiration and is now used as a standard of care. Many tri-
als have also been performed with surfactant as therapy for
acute respiratory distress syndrome. This review article fo-
cuses on the role of surfactant in a variety of subacute dis-
eases. While much remains to be learned, both clinical and
laboratory data continue to provide insights that might pro-
vide novel treatments in the future.
Abbreviations
BAL = bronchoalveolar lavage; CF = cystic fibrosis; COPD = chronic 
obstructive pulmonary disease; GM-CSF = granulocyte-macrophage 
colony-stimulating factor; IPF = idiopathic pulmonary fibrosis; PAP = 
pulmonary alveolar proteinosis; PC = phosphatidylcholine; SP = sur-
factant-associated protein; SP-A/PL = surfactant-associated protein-A/
phospholipid ratio.
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